Energy balance and cancer prognosis, breast cancer

Cancer Prevention and Management through Exercise and Weight Control

Volumn , Issue , 2016, Pages 405-435

  Goodwin, Pamela J ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85123746327     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (120)

1. Abe R, Kumagai N, Kimura M, Hirosaki A, Nakamura T. Biological characteristics of breast cancer in obesity. Tohoku J Exp Med 1976; 120:351-359
2. Donegan WL, Hartz AJ, Rimm AA. The association of body weight with recurrent cancer of the breast. Cancer 1978; 41:1590-1594.
3. Donegan WL, Jayich S, Koehler MR, Donegan JH. The prognostic implications of obesity for the surgical cure of breast cancer. Breast Dis Breast. 1978; 4:14-17.
4. Sohrabi A, Sandoz J, Spratt JS, Polk HC Jr. Recurrence of breast cancer. Obesity, tumor size, and axillary lymph node metastases. JAMA 1980; 244:264-265.
5. Boyd NF, Campbell JE, Germanson T, Thomson DB, Sutherland DJ, Meakin JW. Body weight and prognosis in breast cancer. J Natl Cancer Inst 1981; 67:785-789.
6. Tartter PI, Papatestas AE, Ioannovich J, Mulvihill MN, Lesnick G, Aufses AH Jr. Cholesterol and obesity as prognostic factors in breast cancer. Cancer 1981; 47:2222-2227.
7. ZumoffB, Gorzynski JG, Katz JL, Weiner H, Levin J, Holland J, Fukushima DK. Nonobesity at the time of mastectomy is highly predictive of 10-year disease-free survival in women with breast cancer. Anticancer Res 1982; 2:59-62.
8. Eberlein T, Simon R, Fisher S, Lippman ME. Height, weight, and risk of breast cancer relapse. Breast Cancer Res Treat 1985; 5:81-86.
9. Heasman KZ, Sutherland HJ, Campbell JA, Elhakim T, Boyd NF. Weight gain during adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 1985; 5:195-200.
10. Gregorio DI, Emrich LJ, Graham S, Marshall JR, Nemoto T. Dietary fat consumption and survival among women with breast cancer. J Natl Cancer Inst 1985; 75:37-41.
11. Ownby HE, Frederick J, Russo J, Brooks SC, Swanson GM, Heppner GH, Brennan MJ. Racial differences in breast cancer patients. J Natl Cancer Inst 1985; 75:55-60.
12. Greenberg ER, Vessey MP, McPherson K, Doll R, Yeates D. Body size and survival in premenopausal breast cancer. Br J Cancer 1985; 51:691-697.
13. Newman SC, Miller AB, Howe GR. A study of the effect of weight and dietary fat on breast cancer survival time. Am J Epidemiol 1986; 123:767-774.
14. McNee RK, Mason BH, Neave LM, Kay RG. Influence of height, weight, and obesity on breast cancer incidence and recurrence in Auckland, New Zealand. Breast Cancer Res Treat 1987; 9:145-150.
15. Mohle-Boetani JC, Grosser S, Whittemore AS, Malec M, Kampert JB, Paffenbarger RS Jr. Body size, reproductive factors, and breast cancer survival. Prev Med 1988; 17:634-642.
16. Goodwin PJ, Panzarella T, Boyd NF. Weight gain in women with localized breast cancer - a descriptive study. Breast Cancer Res Treat 1988; 11:59-66.
17. Hebert JR, Augustine A, Barone J, Kabat GC, Kinne DW, Wynder EL. Weight, height and body mass index in the prognosis of breast cancer: early results of a prospective study. Int J Cancer 1988; 42:315-318.
18. Suissa S, Pollak M, Spitzer WO, Margolese R. Body size and breast cancer prognosis: a statistical explanation of the discrepancies. Cancer Res 1989; 49:3113-3116.
19. Lees AW, Jenkins HJ, May CL, Cherian G, Lam EW, Hanson J. Risk factors and 10-year breast cancer survival in northern Alberta. Breast Cancer Res Treat 1989; 13:143-151.
20. Tretli S, Haldorsen T, Ottestad L. The effect of premorbid height and weight on the survival of breast cancer patients. Br J Cancer 1990; 62:299-303.
21. Kyogoku S, Hirohata T, Takeshita S, Nomura Y, Shigematsu T, Horie A. Survival of breast-cancer patients and body size indicators. Int J Cancer 1990; 46:824-831.
22. Kimura M. Obesity as prognostic factors in breast cancer. Diabetes Res Clin Pract 1990; 10(suppl 1):S247-S251.
23. Coates RJ, Clark WS, Eley JW, Greenberg RS, Huguley CM Jr, Brown RL. Race, nutritional status, and survival from breast cancer. J Natl Cancer Inst 1990; 82:1684-1692.
24. Ewertz M, Gillanders S, Meyer L, Zedeler K. Survival of breast cancer patients in relation to factors which affect the risk of developing breast cancer. Int J Cancer 1991; 49:526-530.
25. Nomura AM, Marchand LL, Kolonel LN, Hankin JH. The effect of dietary fat on breast cancer survival among Caucasian and Japanese women in Hawaii. Breast Cancer Res Treat 1991; 18(suppl 1):S135-S141.
26. Vatten LJ, Foss OP, Kvinnsland S. Overall survival of breast cancer patients in relation to preclinically determined total serum cholesterol, body mass index, height and cigarette smoking: a population-based study. Eur J Cancer 1991; 27:641-646.
27. Gordon NH, Crowe JP, Brumberg DJ, Berger NA. Socioeconomic factors and race in breast cancer recurrence and survival. Am J Epidemiol 1992; 135:609-618.
28. Senie RT, Rosen PP, Rhodes P, Lesser ML, Kinne DW. Obesity at diagnosis of breast carcinoma influences duration of disease-free survival. Ann Intern Med 1992; 116:26-32.
29. Tornberg S, Carstensen J. Serum beta-lipoprotein, serum cholesterol and Quetelet's index as predictors for survival of breast cancer patients. Eur J Cancer 1993; 29A:2025-2030.
30. Bastarrachea J, Hortobagyi GN, Smith TL, Kau SW, Buzdar AU. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med 1994; 120:18-25.
31. Katoh A, Watzlaf VJ, D'Amico F. An examination of obesity and breast cancer survival in postmenopausal women. Br J Cancer 1994; 70:928-933.
32. Holmberg L, Lund E, Bergstrom R, Adami HO, Meirik O. Oral contraceptives and prognosis in breast cancer: effects of duration, latency, recency, age at first use and relation to parity and body mass index in young women with breast cancer. Eur J Cancer 1994; 30A:351-354.
33. Jain M, Miller AB. Premorbid body size and the prognosis of women with breast cancer. Int J Cancer 1994; 59:363-368.
34. Obermair A, Kurz C, Hanzal E, Bancher-Todesca D, Thoma M, Bodisch A, Kubista E, Kyral E, Kaider A, Sevelda P, Gitsch G. The influence of obesity on the disease-free survival in primary breast cancer. Anticancer Res 1995; 15:2265-2269.
35. den Tonkelaar I, de Waard F, Seidell JC, Fracheboud J. Obesity and subcutaneous fat patterning in relation to survival of postmenopausal breast cancer patients participating in the DOM-project. Breast Cancer Res Treat 1995; 34:129-137.
36. Zhang S, Folsom AR, Sellers TA, Kushi LH, Potter JD. Better breast cancer survival for postmenopausal women who are less overweight and eat less fat. The Iowa Women's Health Study. Cancer 1995; 76:275-283.
37. Maehle BO, Tretli S. Premorbid body mass index in breast cancer: reversed effect on survival in hormone receptor negative patients. Breast Cancer Res Treat 1996; 41:123-130.
38. Rosner GL, Hargis JB, Hollis DR, Budman DR, Weiss RB, Henderson IC, Schilsky RL. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol 1996; 14:3000-3008.
39. Lethaby AE, Mason BH, Harvey VJ, Holdaway IM. Survival of women with node negative breast cancer in the Auckland region. NZ Med J 1996; 109:330-333.
40. Haybittle J, Houghton J, Baum M. Social class and weight as prognostic factors in early breast cancer. Br J Cancer 1997; 75:729-733.
41. Newman SC, Lees AW, Jenkins HJ. The effect of body mass index and estrogen receptor level on survival of breast cancer patients. Int J Epidemiol 1997; 26:484-490.
42. Jain M, Miller AB. Tumor characteristics and survival of breast cancer patients in relation to premorbid diet and body size. Breast Cancer Res Treat 1997; 42:43-55.
43. Galanis DJ, Kolonel LN, Lee J, Le Marchand L. Anthropometric predictors of breast cancer incidence and survival in a multi-ethnic cohort of female residents of Hawaii, United States. Cancer Causes Control 1998; 9:217-224.
44. Hebert JR, Hurley TG, Ma Y. The effect of dietary exposures on recurrence and mortality in early stage breast cancer. Breast Cancer Res Treat 1998; 51:17-28.
45. Menon KV, Hodge A, Houghton J, Bates T. Body mass index, height and cumulative menstrual cycles at the time of diagnosis are not risk factors for poor outcome in breast cancer. Breast 1999; 8:328-333.
46. Kumar NB, Cantor A, Allen K, Cox CE. Android obesity at diagnosis and breast carcinoma survival: evaluation of the effects of anthropometric variables at diagnosis, including body composition and body fat distribution and weight gain during life span, and survival from breast carcinoma. Cancer 2000; 88:2751-2757.
47. Marret H, Perrotin F, Bougnoux P, Descamps P, Hubert B, Lefranc T, Le Floch O, Lansac J, Body G. Low body mass index is an independent predictive factor of local recurrence after conservative treatment for breast cancer. Breast Cancer Res Treat 2001; 66:17-23.
48. Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL. Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer 2001; 92:720-729.
49. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002; 20:42-51.
50. Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 2003; 95:1467-1476.
51. Carmichael AR, Bendall S, Lockerbie L, Prescott RJ, Bates T. Does obesity compromise survival in women with breast cancer? Breast 2004; 13:93-96.
52. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 2002; 20:1128-1143.
53. Boyd DB. Insulin and cancer. Integr Cancer Ther 2003; 2:315-329.
54. Dixon JK, Moritz DA, Baker FL. Breast cancer and weight gain: an unexpected finding. Oncol Nursing Forum 1978; 5:5-7.
55. Knobf MK, Mullen JC, Xistris D, Moritz DA. Weight gain in women with breast cancer receiving adjuvant chemotherapy. Oncol Nursing Forum 1983; 10:28-33.
56. Bonomi P, Bunting N, Fishman D, Wolter J, Hernandez A, Foltz W, Shorey A, Straus A, Anderson K, Roseman D, Economou S. Weight gain during adjuvant chemotherapy or hormono-chemotherapy for stage II breast cancer evaluated in relation to disease free survival (DFS) (abstr.). Breast Cancer Res Treat 1984; 4:339.
57. Huntington MO. Weight gain in patients receiving adjuvant chemotherapy for carcinoma of the breast. Cancer 1985; 56:472-474.
58. Chlebowski RT, Weiner JM, Reynolds R, Luce J, Bulcavage L, Bateman JR. Long-term survival following relapse after 5-FU but not CMF adjuvant breast cancer therapy. Breast Cancer Res Treat 1986; 7:23-30.
59. Camoriano JK, Loprinzi CL, Ingle JN, Therneau TM, Krook JE, Veeder MH. Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol 1990; 8:1327-1334.
60. Foltz AT. Weight gain among stage II breast cancer patients: a study of five factors. Oncol Nursing Forum 1985; 12:21-26.
61. DeGeorge D, Gray JJ, Fetting JH, Rolls BJ. Weight gain in patients with breast cancer receiving adjuvant treatment as a function of restraint, disinhibition, and hunger. Oncol Nursing Forum 1990; 17:23-28.
62. Levine EG, Raczynski JM, Carpenter JT. Weight gain with breast cancer adjuvant treatment. Cancer 1991; 67:1954-1959.
63. Hoskin PJ, Ashley S, Yarnold JR. Weight gain after primary surgery for breast cancer - effect of tamoxifen. Breast Cancer Res Treat 1992; 22:129-132.
64. Hupperets PS, Wils J, Volovics L, Schouten L, Fickers M, Bron H, Schouten HC, Jager J, Smeets J, de Jong J, Blijham GH. Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients. Ann Oncol 1993; 4:295-301.
65. Kumar NB, Allen K, Cantor A, Cox CE, Greenberg H, Shah S, Lyman GH. Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact? Breast Cancer Res Treat 1997; 44:135-143.
66. Cheney CL, Mahloch J, Freeny P. Computerized tomography assessment of women with weight changes associated with adjuvant treatment for breast cancer. Am J Clin Nutr 1997; 66:141-146.
67. Sitzia J, Huggins L. Side effects of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy for breast cancer. Cancer Pract 1998; 6:13-21.
68. Rock CL, Flatt SW, Newman V, Caan BJ, Haan MN, Stefanick ML, Faerber S, Pierce JP. Factors associated with weight gain in women after diagnosis of breast cancer. Women's Healthy Eating and Living Study Group. J Am Diet Assoc 1999; 99:1212-1221.
69. Goodwin PJ, Ennis M, Pritchard KI, McCready D, Koo J, Sidlofsky S, Trudeau M, Hood N, Redwood S. Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol 1999; 17:120-129.
70. McInnes JA, Knobf MT. Weight gain and quality of life in women treated with adjuvant chemotherapy for early-stage breast cancer. Oncol Nursing Forum 2001; 28:675-684.
71. Costa LJ, Varella PC, del Giglio A. Weight changes during chemotherapy for breast cancer. Sao Paulo Med J 2002; 120:113-117.
72. Del Rio G, Zironi S, Valeriani L, Menozzi R, Bondi M, Bertolini M, Piccinini L, Banzi MC, Federico M. Weight gain in women with breast cancer treated with adjuvant cyclophosphomide, methotrexate and 5-fluorouracil. Analysis of resting energy expenditure and body composition. Breast Cancer Res Treat 2002; 73:267-273.
73. Lankester KJ, Phillips JE, Lawton PA. Weight gain during adjuvant and neoadjuvant chemotherapy for breast cancer: an audit of 100 women receiving FEC or CMF chemotherapy. Clin Oncol (R Coll Radiol) 2002; 14:64-67.
74. Grindel CG, Cahill CA, Walker M. Food intake of women with breast cancer during their first six month of chemotherapy. Oncol Nursing Forum 1989; 16:401-407.
75. Winningham ML, MacVicar MG, Bondoc M, Anderson JI, Minton JP. Effect of aerobic exercise on body weight and composition in patients with breast cancer on adjuvant chemotherapy. Oncol Nursing Forum 1989; 16:683-689.
76. Boyar AP, Rose DP, Loughridge JR, Engle A, Palgi A, Laakso K, Kinne D, Wynder EL. Response to a diet low in total fat in women with postmenopausal breast cancer: a pilot study. Nutr Cancer 1988; 11:93-99.
77. Nordevang E, Ikkala E, Callmer E, Hallstrom L, Holm LE. Dietary intervention in breast cancer patients: effects on dietary habits and nutrient intake. Eur J Clin Nutr 1990; 44:681-687.
78. Demark-Wahnefried W, Hars V, Conaway MR, Havlin K, Rimer BK, McElveen G, Winer EP. Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. Am J Clin Nutr 1997; 65:1495-1501.
79. Aslani A, Smith RC, Allen BJ, Pavlakis N, Levi JA. Changes in body composition during breast cancer chemotherapy with the CMF-regimen. Breast Cancer Res Treat 1999; 57:285-290.
80. Kutynec CL, McCargar L, Barr SI, Hislop TG. Energy balance in women with breast cancer during adjuvant treatment. J Am Diet Assoc 1999; 99:1222-1227.
81. Schwartz AL. Exercise and weight gain in breast cancer patients receiving chemotherapy. Cancer Pract 2000; 8:231-237.
82. Rock CL, McEligot AJ, Flatt SW, Sobo EJ, Wilfley DE, Jones VE, Hollenbach KA, Marx RD. Eating pathology and obesity in women at risk for breast cancer recurrence. Int J Eat Disord 2000; 27:172-179.
83. Demark-Wahnefried W, Peterson BL, Winer EP, Marks L, Aziz N, Marcom PK, Blackwell K, Rimer BK. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2001; 19:2381-2389.
84. Schmid P, Untch M, Wallwiener D, Kosse V, Bondar G, Vassiljev L, Tarutinov V, Kienle E, Luftner D, Possinger K. Cyclophosphamide, methotrexate and fluorouracil (CMF) vs. hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast Cancer Study with Leuprorelin Acetate). Anticancer Res 2002; 22:2325-2332.
85. Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, Camps C, Carrato A, Casado A, Candel MT, Albanell J, Aranda J, Munarriz B, Campbell J, Diaz-Rubio E. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) vs. methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol 2003; 14:833-842.
86. Freedman RJ, Aziz N, Albanes D, Hartman T, Danforth D, Hill S, Sebring N, Reynolds JC, Yanovski JA. Weight and body composition changes during and after adjuvant chemotherapy in women with breast cancer. J Clin Endocrinol Metab 2004; 89:2248-2253.
87. Harvie MN, Campbell IT, Baildam A, Howell A. Energy balance in early breast cancer patients receiving adjuvant chemotherapy. Breast Cancer Res Treat 2004; 83:201-210.
88. Bonadonna G, Valagussa P, Rossi A, Tancini G, Brambilla C, Zambetti M, Veronesi U. Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 1985; 5:95-115.
89. De Conti RC. Weight gain in the adjuvant chemotherapy of breast cancer. Proc Am Soc Clin Oncol 1982; 1:73.
90. Kumar N, Allen KA, Riccardi D, Bercu BB, Cantor A, Minton S, Balducci L, Jacobsen PB. Fatigue, weight gain, lethargy and amenorrhea in breast cancer patients on chemotherapy: is subclinical hypothyroidism the culprit? Breast Cancer Res Treat 2004; 83:149-159.
91. Stephenson GD, Rose DP. Breast cancer and obesity: an update. Nutr Cancer 2003; 45:1-16.
92. Goodwin PJ, Esplen MJ, Winocur J, Butler K, Pritchard KI. Development of a weight management program in women with newly diagnosed locoregional breast cancer. In: Bitzer J. and Stauber M. Eds. International Society of Psychosomatic Obstetrics and Gynaecology: Psychosomatic Obstetrics and Gynecology. Italy: Monduzzi Editore, International Proceedings, 1995:491-496.
93. Ballard-Barbash R. Chap. 14, this volume.
94. Williams G, Howell A, Jones M. The relationship of body weight to response to endocrine therapy, steroid hormone receptors and survival of patients with advanced cancer of the breast. Br J Cancer 1988; 58:631-634.
95. Kamby C, Ejlertsen B, Andersen J, Birkler NE, Rytter L, Zedeler K, Rose C. Body size and menopausal status in relation to the pattern of spread in recurrent breast cancer. Acta Oncol 1989; 28:795-799.
96. Kornblith AB, Hollis DR, Zuckerman E, Lyss AP, Canellos GP, Cooper MR, Herndon JE, Phillips CA, Abrams J, Aisner J, Norton L, Henderson C, Holland JC. Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B. J Clin Oncol 1993; 11:2081-2089.
97. Shepherd L, Parulekar W, Day A, Ottaway J, Bramwell V, Levine M, Pritchard K. Weight gain during adjuvant therapy in high-risk pre/perimenopausal breast cancer patients: Analysis of a National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) phase II study (abstr.). Proc Am Soc Clin Oncol 2001; 20:36a.
98. Goodwin P, Esplen MJ, Butler K, Winocur J, Pritchard K, Brazel S, Gao J, Miller A. Multidisciplinary weight management in locoregional breast cancer: results of a phase II study. Breast Cancer Res Treat 1998; 48:53-64.
99. Bonomi P, Bunting N, Fishman D, Wolter J, Hernandez B, Foltz A, Shorey W, Straus A, Anderson K, Roseman D, Economou S. Weight gain during adjuvant chemotherapy or hormono-chemotherapy for stage II breast cancer evaluated in relation to disease free survival (DFS) (abstr.). Br Cancer Res Treat 1984; 4:339.
100. Madarnas Y, Sawka CA, Franssen E, Bjarnason GA. Are medical oncologists biased in their treatment of the large woman with breast cancer? Breast Cancer Res Treat 2001; 66:123-133.
101. Schmid P, Possinger K, Bohm R, Chaudri H, Verbeek A, Grosse Y, Luftner D, Petrides P, Sezer O, Wischnewsky M. Body mass index as predictive parameter for response and time to progression (TTP) in advanced breast cancer patients treated with letrozole or megestrol acetate (abstr.). Proc Am Soc Clin Oncol 2000; 19:103a.
102. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
103. Shen BJ, Todaro JF, Niaura R, McCaffery JM, Zhang J, Spiro A, III, Ward KD. Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. Am J Epidemiol 2003; 157:701-711.
104. Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D, Frittitta L, Vannelli GB, Brand R, Goldfine ID, Vigneri R. Elevated insulin receptor content in human breast cancer. J Clin Invest 1990; 86:1503-1510.
105. Hwang DL, Papoian T, Barseghian G, Josefsberg Z, Lev-Ran A. Absence of down-regulation of insulin receptors in human breast cancer cells (MCF-7) cultured in serum-free medium: comparison with epidermal growth factor. J Recept Res 1985; 5:27-43.
106. Mountjoy KG, Finlay GJ, Holdaway IM. Abnormal insulin-receptor down regulation and dissociation of down regulation from insulin biological action in cultured human tumor cells. Cancer Res 1987; 47:6500-6504.
107. Jackson JG, White MF, Yee D. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J Biol Chem 1998; 273:9994-10003.
108. Zong CS, Zeng L, Jiang Y, Sadowski HB, Wang LH. Stat3 plays an important role in oncogenic Rosand insulin-like growth factor I receptor-induced anchorage-independent growth. J Biol Chem 1998; 273:28065-28072.
109. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000; 183:1-9.
110. ResnicoffM, Baserga R. The role of the insulin-like growth factor I receptor in transformation and apoptosis. Ann NY Acad Sci 1998; 842:76-81.
111. Blackburn G, Waltman B. Chap. 20, this volume.
112. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002; 94:972-980.
113. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Hartwick W, Hoffma B, Hood N. Insulinlike growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Res Treat 2002; 74:65-76.
114. Rose DP, Gilhooly EM, Nixon DW. Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin (review). Int J Oncol 2002; 21:1285-1292.
115. Goodwin PJ, Ennis M, Fantus IG, Pritchard KI, Trudeau ME, Koo J, Hood N. Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? J Clin Oncol. (in press).
116. Peiris AN, Sothmann MS, Aiman EJ, Kissebah AH. The relationship of insulin to sex hormone-binding globulin: role of adiposity. Fertil Steril 1989; 52:69-72.
117. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72:83-89.
118. Oesterreich S, Zhang P, Guler RL, Sun X, Curran EM, Welshons WV, Osborne CK, Lee AV. Reexpression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res 2001; 61:5771-5777.
119. Dupont J, Le Roith D. Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects. Mol Pathol 2001; 54:149-154.
120. Dupont J, Karas M, LeRoith D. The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components. J Biol Chem 2000; 275:35893-35901.